Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05283330 · ClinicalTrials.gov registry record · Phase 1

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

A Phase 1 study of Breast Cancer and Glioblastoma, sponsored by Orano Med.

Recruiting
Registry status
Phase 1
Development phase
48
Enrollment target
4
Study locations

NCT05283330 is a Phase 1 study of Breast Cancer and Glioblastoma that is actively recruiting participants, run by Orano Med. The registered enrollment target is 48 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05283330, a Phase 1 study of Breast Cancer and Glioblastoma, is actively recruiting participants, sponsored by Orano Med.

RECRUITING
Registry status
Phase 1
Development phase
48 participants
Enrollment target
4
Study locations

Study Summary

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

Conditions Studied

Breast Cancer Glioblastoma Cervical Cancer Colon Cancer NSCLC Nonsmall Cell Lung Cancer mCRPC (Metastatic Castration-resistant Prostate Cancer)

Interventions

  • DRUG ²¹²Pb-DOTAM-GRPR1

Study Locations (4)

Illinois

  • Northwestern University Robert H Lurie Medical Research - Chicago

Kentucky

  • UK Markey Cancer Center - Lexington

Maryland

  • Advanced Molecular Imaging and Therapy - Glen Burnie

Nebraska

  • XCancer Omaha / Urology Cancer Center - Omaha

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2022-12-22
Est. Completion 2032-05
Phase Phase 1

Sponsor

Orano Med

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05283330

The ClinicalTrials.gov registry entry for NCT05283330 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Orano Med, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which ²¹²Pb-DOTAM-GRPR1 is the first listed.

NCT05283330 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Kentucky, Maryland.

Frequently Asked Questions

What is clinical trial NCT05283330 about?

NCT05283330 is a clinical study titled "Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors". A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

What is the current status of trial NCT05283330?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2022-12-22. Estimated completion is 2032-05.

What conditions does trial NCT05283330 study?

This clinical trial studies the following conditions: Breast Cancer, Glioblastoma, Cervical Cancer, Colon Cancer, NSCLC.

What interventions are being tested in trial NCT05283330?

The interventions under investigation include: ²¹²Pb-DOTAM-GRPR1 (DRUG).

Who is sponsoring clinical trial NCT05283330?

This trial is sponsored by Orano Med, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05283330 being conducted?

This trial has 4 study locations across Illinois, Kentucky, Maryland, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Glioblastoma

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.